Harvard Business Review

MAY 8, 2013

I recently conducted a study of 56 randomly selected companies involved in major change and innovation efforts in the high-tech, retail, pharmaceutical, banking, automotive, insurance, energy, non-profit, and health care industries. Nearly 68% of these large-scale change and innovative efforts failed.

Middle Management 11

Middle Management Management Automotive Pharmaceuticals 11

Harvard Business Review

DECEMBER 23, 2016

What distinguished successful from unsuccessful alliances was more of a “productive” irritation — creative tension between differing ideas about how to develop alliance products – reflected in disagreements about the strategy and tactics of how best to develop a particular molecule.

Productivity 8

Productivity Products Survey Strategic Fit 8

Harvard Business Review

OCTOBER 27, 2015

In most companies, marketers are in charge of assessing the competition. Because of this, close to 60 percent of all competitive intelligence professionals report to marketing. Yet the majority of marketers fail to use their competition analysts strategically, instead using them to gather more “recon” data.

Marketing 8

Marketing Competitive Intelligence Porter How To 8

Harvard Business Review

NOVEMBER 2, 2018

Competing for scarce labor in a tight market, they will have trouble continuing to shift medical bills onto employees as they have for several decades. To address these challenges, they will have to band together in purchasing coalitions that give them the local market power to force health systems to reform. Tim Robberts/Getty Images.

Health Care 8

Health Care Cost Insurance Price 8

Strategy Driven

JANUARY 24, 2011

Closing the Execution Gap : How Great Leaders and Their Companies Get Results by Richard Lepsinger If an organization can’t execute its plans and initiatives, nothing else matters: not the most solid, well thought-out strategy, not the most innovative business model, not even technological breakthroughs that could transform an industry.

Execution 67

Execution Company 360-Degree Feedback Cooper 67

Harvard Business Review

DECEMBER 19, 2014

As two of his business units were completing their merger, Peter Noll, chief of the Diagnostics division at the Frankfurt-based Scherr Pharmaceuticals, felt it was time to address a nagging issue: The combined entity had no overarching revenue model. There seemed little point. But all patents expire. ” “Counterproductive? .”

Case Study 13

Case Study Price Chemicals Strategy 13

Harvard Business Review

APRIL 6, 2017

The 1984 Drug Price Competition and Patent Term Restoration Act gave pharmaceutical companies exclusive protections for innovating a new drug. If they brought a new therapy to life, they enjoyed patent protection to effectively monopolize the market. “Authorized generics” are another tactic to limit competition.

System 15

System Pharmaceuticals Company Sample 15